The blood transfusion diagnostics market size is estimated to be USD 4, 296.6 million in 2022 and is expected to witness a CAGR of 7.21% during the forecast period 2023-2033. Surge in incidence of trauma, car accidents, surgeries, and childbirth cases, increasing blood donation initiatives, and development of new technologies to facilitate blood donation and storage are factors contributing to the market growth. Furthermore, U.S. FDA’s rising rate of approval of blood transfusion diagnostics devices is projected to fuel the market growth. However, lack of highly qualified technologists for blood transfusion services and a worldwide decrease in blood donation rates is expected to hinder the growth.

Surge in incidence of trauma, car accidents, surgeries, and childbirth cases are expected to drive the market growth. The CDC estimates that there are approximately 6 million car accidents in the United States each year. There are over 3 million injuries among them. According to the WHO 2018 study, around 50 million road traffic injuries occur annually worldwide. Additionally, platelet transfusions are required for procedures including post-cardiopulmonary bypass, neurosurgery, posterior eye surgery, and chronic bleeding problems.

Increasing blood donation initiatives is predicted to propel the market growth. Give blood and keep the world beating was the campaign’s tagline for 2021. The WHO’s campaign this year was primarily focused on inspiring young people to donate blood and ensuring a secure blood supply. The demand for blood transfusion diagnostics is predicted to reach pre-COVID-19 levels as economies ease their regulations and more blood donation drives are held throughout the globe. For instance, from October 2021 to March 2022, the Indian blood collecting company e-RaktKash has 53 campaigns scheduled all around the country.

Segmentation

By Product

The market is categorized into instruments, reagents & kits, and others. In 2022, the reagents & kits segment accounted for the highest revenue share due to the availability of products and the repeated purchase of these products needed to screen donor and recipient sample. Another aspect driving the segmental rise is the accessibility of a broad range of blood grouping, typing, and donor screening reagents, kits, and assays produced by both international and local players. This market has grown profitably due to the accessibility of highly effective donor screening analyzers. For instance, completely automated platform MosaiQ by Quotient is used to screen donor samples for TTI and perform blood grouping. Additionally, the growing availability of quick diagnostic kits for secure blood transfusion is anticipated to fuel market expansion over the next few years.

By Application

The market is categorized into disease screening and blood screening. In the global market, the disease screening segment accounted for the largest revenue share in 2022 owing to high incidence of transfusion-transmitted infections, higher blood donation safety screening to maintain safe transfusion, increasing technical improvements, and broad product portfolios provided by key market competitors. In addition, the market is anticipated to be driven by the increasing emphasis on conducting experiments with serological testing procedures in various research studies. For instance, a research evaluation of the seroprevalence of SARS-CoV-2 antibodies among blood donors in the Chinese cities of Wuhan, Shenzhen, and Shijiazhuang was published in Nature Communication in 2021. The demand for blood transfusion diagnostics products would rise as a result of such studies.

By End User

The market is segmented into blood banks, hospitals, diagnostic laboratories, and others. In 2022, the blood banks segment accounted for the largest revenue share owing to numerous disease screening and blood-typing procedures carried out prior to transfusion therapy. By thoroughly screening for diseases and adhering to the rules, these facilities are increasingly ensuring the safety of the blood supply. Blood typing, Rh typing, unexpected RBC antibody screening, and infectious disease screening are a few of the common tests carried out in these end-use settings using the donated blood. Over 10% of hospital patients need blood transfusions. Accident victims are often admitted to emergency rooms, in which this percentage is higher. Hospitals are required to screen donated blood for infections, conduct tests to determine the compatibility of the donor and the receiver as part of pretransfusion therapy, and establish standards for haematological components. As a result, in 2022, the hospitals sector accounted for large shares.

Regional Markets

In 2022, North America region accounted for the highest revenue in the blood transfusion diagnostics market and is expected to maintain its dominance during the forecast period. This is attributed to the rising health consciousness, increasing disposable income, favourable reimbursement policies, and well-established healthcare infrastructure. 43,000 pints of donated blood are used each day in the United States and Canada, according to data from the Community Blood Center. In North America, the U.S. had the largest share. Its dominance is largely due to the local involvement of key market players, the accessibility of numerous diagnostic assays, and the more than 600 independent donation facilities. Over 60% of blood donations in the United States are collected by independent blood centres, and supply 25% of the blood supply in Canada. The blood transfusion diagnostics market is anticipated to expand at the fastest rate in Asia Pacific during the forecast period. Regional development is being promoted by growing blood donor awareness and launching several initiatives in Australia and India.

Competitor Insights

Some of the key players operating in the blood transfusion diagnostics market are Abbott, BAG Healthcare GmbH, F. Hoffmann-La Roche AG, DiaSorin S.P.A., Quotient Limited, Immucor, Inc., Ortho Clinical Diagnostics, Danaher, Bio-Rad Laboratories, and BIO KIT (Werfen).

To achieve a competitive edge, these businesses are implementing a variety of growth strategies. Strategic partnerships, alliances, and agreements with different businesses and research institutions are seen to be the main strategies used by companies in this sector.

• For instance, Hemanext, a developer of blood storage technology, stated in September 2021 that it will raise USD 100 million in private equity and USD 15 million through a new series A funding round. The Hemanext One System processes are intended to be expanded globally. The product can be sold in Europe due to its CE mark.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including product, application, and end user from 2023 to 2033.

Report Scope:

Segmentation: Blood Transfusion Diagnostics Market Report 2022 – 2033

Product (Revenue, USD Million), 2022 – 2033

• Instruments
• Reagents & Kits
• Others

Application (Revenue, USD Million), 2022 – 2033

• Disease Screening
  • Molecular Disease Screening
  • Serological Disease Screening
• Blood Screening

End user (Revenue, USD Million), 2022 – 2033

• Blood Banks
• Hospitals
• Diagnostic Laboratories
• Others

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA